Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection

Kühne, Christian; Heufelder, Armin E.; Hofbauer, Lorenz C.

doi:10.1359/jbmr.2001.16.1.2

Cited by 36 publications

(21 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(18) Similarly, DHEA was, as previously reported, (19) slightly decreased in patients treated without PI but it is not likely that it can account for the decreased bone density. There was no vitamin D deficiency or increase in PTH level.…”

Section: Ameil Et Alsupporting

confidence: 54%

BMD Is Reduced in HIV-Infected Men Irrespective of Treatment

Amiel

Ostertag

Slama

et al. 2004

Journal of Bone and Mineral Research

136

View full text Add to dashboard Cite

show abstract

Section: Ameil Et Alsupporting

confidence: 54%

BMD Is Reduced in HIV-Infected Men Irrespective of Treatment

Amiel

Ostertag

Slama

et al. 2004

Journal of Bone and Mineral Research

136

View full text Add to dashboard Cite

show abstract

“…These children also have poorer nutritional status and lower intake of vitamin containing food. HIV-infected patients may have impaired 1α-hydroxylation that decreases production and action of the active vitamin D metabolite 1,25(OH 2 D 3 ) despite normal vitamin D levels 36 . Some ART such as PI and efavirenz, suppress the activity of 25 and 1α-hydroxylase or activates the destruction of 25-OHD and 1,25(OH 2 D 3 ) to inactivate calcitroic acid 23, 29 .…”

Section: Discussionmentioning

confidence: 99%

“…Some ART such as PI and efavirenz, suppress the activity of 25 and 1α-hydroxylase or activates the destruction of 25-OHD and 1,25(OH 2 D 3 ) to inactivate calcitroic acid 23, 29 . Higher rate of vitamin D deficiency may be explained by exposure to antiretroviral drugs especially efavirenz 37 On the other hand, PTH levels could be lower than expected in HIV-infected patients because PTH secretion is inhibited by pro-inflammatory cytokines 29, 36 and PTH resistance has been reported in HIV infection 36 . ART also altered the PTH secretion in both directions 29, 34, 38 .…”

Section: Discussionmentioning

confidence: 99%

Prevalence and Risk Factors of Low Bone Mineral Density Among Perinatally HIV-Infected Thai Adolescents Receiving Antiretroviral Therapy

Puthanakit

Saksawad

Bunupuradah

et al. 2012

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background Low bone mineral density (BMD) has been reported among 10–54% of HIV-infected adolescents in developed countries. We studied the prevalence and predictors of low BMD among HIV-infected Thai adolescents receiving antiretroviral therapy. Methods A cross-sectional study of lumbar spine (L2–L4) BMD as measured by dual-energy X-ray absorptiometry (DXA) in Thai HIV-infected adolescents aged 12–20 years was performed. The BMD Z-score was analyzed using age-matched healthy Thai children as a reference. Serum 25-hydroxyvitamin D (25-OHD) was performed. Osteopenia was defined as BMD Z-score≤ −2. Results From October 2010 to February 2011, 101 adolescents, 50% male, with a median age of 14.3 (range, 13.0–15.7) years were enrolled. The median (IQR) current CD4 T-cell count was 646 (506–796) cells/mm3 and 90% had plasma HIV-1 RNA <50 copies/ml. The mean BMD among HIV-infected adolescents and controls were 0.855 and 0.980 g/cm2(P<0.001). The median (IQR) L2–L4 spine BMD Z-score was −1.0 (−1.9 to −0.1), of which 24% had BMD Z-score ≤ −2.0. The median (IQR) of 25-OHD level was 24.8 (20.0–31.4) ng/ml, of which 25% had vitamin D level < 20 ng/ml. In multivariate analysis, the height for age Z-score <−1.5 (adjusted odds ratio (aOR) 6.2; 95% CI 2.2–17.7) and history of WHO clinical stage 4 prior to ART (aOR 3.7; 95%CI 1.3–10.7) were significantly associated with osteopenia. Conclusion One-fourth of HIV-infected Thai adolescents have osteopenia. Children with history of advanced- staging or having low height for age are at risk of osteopenia. Preventive measures to prevent osteopenia should be incorporated in routine care for these adolescents.

show abstract

“…6,[18][19][20] Indeed, the association between these cytokines and bone remodeling has been seen in many osteometabolic diseases, including post-menopausal osteoporosis. 4,5 Our data provide an original contribution to the topic, suggesting that the increased osteoclastic activity might be responsible for BMD loss in this group of patients.…”

Section: Discussionmentioning

confidence: 99%

Reabsorção no metabolismo ósseo de pacientes HIV-positivos

2009

View full text Add to dashboard Cite

INTRODUÇÃO: Pacientes infectados pelo HIV apresentam osteoporose ou osteopenia densitométrica numa taxa de 28 a 50%. O objetivo deste estudo é verificar alterações na taxa de reabsorção/formação destes pacientes. MATERIAL E MÉTODOS: Realizou-se revisão sistemática com metanálise de estudos controlados que avaliaram a associação entre osteopenia e/ou alterações no metabolismo ósseo com a infecção pelo HIV. Todos os estudos que incluíam osteocalcina ou NTX com marcadores respectivos de formação e reabsorção ósseos foram incuidos. Cinco estudos foram classificados como evidência classe III e envolveram 456 indivíduos HIV positivos e 590 controles. O NTX teve aumento significante (p < 0.00014) no grupo HIV-positivo, enquanto osteocalcina não se mostrou alterada. CONCLUSÃO: O presente estudo permite concluir que, durante a infecção pelo HIV, o marcador NTX está significantemente elevado, refletido alta atividade reabsortiva no tecido ósseo. Isto aponta um papel importante na atividade osteoclástica na perda óssea de pacientes HIV-positivos.

show abstract

Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection

Cited by 36 publications

References 101 publications

BMD Is Reduced in HIV-Infected Men Irrespective of Treatment

BMD Is Reduced in HIV-Infected Men Irrespective of Treatment

Prevalence and Risk Factors of Low Bone Mineral Density Among Perinatally HIV-Infected Thai Adolescents Receiving Antiretroviral Therapy

Reabsorção no metabolismo ósseo de pacientes HIV-positivos

Contact Info

Product

Resources

About